실시간
BioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsBioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsBioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo success
Endpoints News 2025년 12월 19일

Senators point fingers over who blocked the rare disease voucher reauthorization

Senators point fingers over who blocked the rare disease voucher reauthorization

본문을 이용할 수 없습니다. 원본 출처를 확인하세요.